- Berkshire Hathaway Rallies to 6-Month Closing High
- Market Insider: Earnings Remain a Tailwind for Stocks
- After Dismal Results, Is Tech Trade Intact?
- Oil Next Week: What Energy Traders Will Be Watching
- Reverse Stock Splits and Unintended Consequences
- As Healthcare Reform Advances, Investors Get Nervous
- Cramer: Starbucks Is Back
- States with Highest Density of Millionaires
- American Airlines Raises Baggage Check Fees
- Market 360: The Week's Best & Worst
- Hirschhorn: Manage Risk or it Will Manage You
- If FINA Ruling Holds, Business Would Change
- Homeownership Society: All in Good Time
- Compliments, Complaints, and the Obama T-Shirt Mystery
- Art Cashin: Dow 10,000 Possible Near-Term
- When Does Palm Stop Acting As Apple Wanna-be?
- Dunkelberg: 'To Raise the Cost of Labor, What is Congress Thinking?'
- Sometimes Fairy Tales Do Come True
- Dodd may snub lobbyists, but not their cash
- Qantas jet turns back as cabin loses air pressure
- Report: 30,000 China steelworkers in deadly clash
- IMF approves $2.6 billion loan to Sri Lanka
- Mexican oil output falls 7.5 percent in first half
- New Ariz. law would allow post-foreclosure suits
- Cool summer disappoints tourists, delays crops
- Dell settles federal discrimination suit for $9.1M
- Cuba visitor a free man, despite his best efforts
Mylan gets FDA OK for generic thyroid drug Cytomel
Text Size 
CANONSBURG, Pa. - Drug developer Mylan Inc. said Thursday it received Food and Drug Administration approval for a generic version of the thyroid deficiency treatment Cytomel.
King Pharmaceuticals Inc. makes the drug, which is called liothyronine sodium, generically. Cytomel had sales of about $54 million during the 12-month period ended March 31, Mylan said.
The thyroid gland regulates metabolism along with body temperature, growth and heart rate.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes